Medline Inc. announces pricing of upsized secondary offering of Class A common stock
Rhea-AI Summary
Medline (Nasdaq: MDLN) priced an upsized secondary offering of 72,554,594 Class A shares by selling stockholders at $37.00 per share. Underwriters have a 30-day option for up to 10,883,189 additional shares. The offering should close on May 28, 2026, and Medline will not receive proceeds.
Positive
- No dilution to existing shareholders, as Medline is not issuing or selling any shares
- Large, underwritten secondary offering may broaden MDLN’s public float and trading volume
Negative
- Medline will not receive any of the cash proceeds from this secondary offering
- Significant block of 72,554,594 shares is being sold by existing large shareholders
News Market Reaction – MDLN
In the May 22 session, MDLN declined 0.24%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | Secondary launch | Negative | -3.4% | Launch of 60M-share secondary by selling stockholders with 9M-share option. |
| Mar 10 | Secondary closing | Negative | -1.2% | Closing of 86.25M-share secondary and full exercise of 11.25M-share option. |
| Mar 04 | Secondary pricing | Negative | +2.7% | Pricing of 75M-share secondary at $41.00 with 11.25M-share option. |
| Mar 03 | Secondary launch | Negative | -3.2% | Launch of 75M-share underwritten offering by private equity sponsors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-related headlines for MDLN have typically seen mildly negative reactions, with an average move of about -1.27% and 3 of 4 past events trading in the same (negative) direction as the perceived overhang risk.
Over recent months, Medline has repeatedly used underwritten secondary offerings for existing holders, with Blackstone, Carlyle, Hellman & Friedman and ADIA selling large Class A blocks. Past offering and pricing announcements between Mar 3–10, 2026 involved transactions from 75,000,000 to 86,250,000 shares, usually with Medline receiving no proceeds. Those events generally produced modestly negative single‑day moves, framing today’s upsized pricing as part of an ongoing sponsor sell‑down.
Key Terms
secondary offering financial
class a common stock financial
underwriters financial
prospectus regulatory
registration statement regulatory
securities and exchange commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of
Medline is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale.
Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers. Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank, Evercore ISI, BMO Capital Markets, BNP Paribas, MUFG, RBC Capital Markets, Santander, Societe Generale, TD Cowen, Wells Fargo Securities, Wolfe | Nomura Alliance, Leerink Partners, Macquarie Capital, Mizuho, Piper Sandler, Truist Securities and William Blair are acting as bookrunning managers, and Blackstone Capital Markets, Carlyle, Baird, Rothschild & Co, Stifel, BTIG, ING, IMI – Intesa Sanpaolo, NCMG, Perella Weinberg, Academy Securities, AmeriVet Securities, Blaylock Van, LLC, C.L. King & Associates, Drexel Hamilton, Loop Capital Markets, Mischler Financial Group, Inc., R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the offering.
The offering of these securities is being made only by means of a prospectus. When available, copies of the prospectus relating to this offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.
A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar conditional or future expressions, are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements related to Medline’s industry, business strategy, costs, and cost savings, goals and expectations, market position, future operations, margins, profitability, annual guidance, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainties, and changes in circumstances, many of which are beyond Medline’s control, that could cause actual results to differ materially.
Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.
Contacts:
Investor Relations:
Karen King
Global Head Investor Relations
Patrick Flaherty
Director, Investor Relations
(847) 247-7222
IR@medline.com
Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
media@medline.com
Source: Medline Inc.
